麝香注射液对脑梗死患者血液流变学及甲襞微循环的影响

目的 探讨麝香注射液对脑梗死患血液流变学及甲襞微循环的影响。方法 对60例脑梗死急随机分成治疗组和对照组，治疗组予麝香注射液，对照组予复方丹参、低分子右旋糖酐治疗。于治疗前后分别测定上述指标。结果 麝香注射液治疗后血液流变学检查各项指标均显下降，且甲襞微循环血液流速流态等均有显改善。结论 麝香注射液能明显改善血液流变学异常及微循环障碍，在防治脑梗死中有重要价值。     

一种有效提高小丸微波干燥能力及质量的装置

介绍一种能提高小丸微波干燥能力,避免小丸干燥开裂、过火等现象,可以提高小丸微波干燥均匀度的装置。     

保心汤治疗冠心病心绞痛气虚血瘀证的临床观察

目的观察保心汤对冠心病心绞痛 (气虚血瘀证 )的疗效。方法采用随机对照方法 ,将 62例病人随机分为保心汤组和西药对照组 ,观察两组心绞痛发作情况及心电图、血脂、临床症状等的变化。结果两组在心绞痛、心电图疗效上无显著性差异 (P >0 .0 5 ) ,但在改善症状和对血脂的影响方面保心汤组优于对照组(P >0 .0 5 )。结论保心汤能有效改善心肌缺血和临床症状 ,对血脂有良性影响     

复方丹参滴丸对急慢性高粘滞血症模型血管内皮细胞分泌功能的影响

目的：观察复方丹参滴丸对高粘滞血症血管内皮分泌功能的影响，探索其作用机制。方法：复合因素(高分子右旋糖酐、肾上腺素、牛血清白蛋白)、长时间(112天)造成高粘滞血症慢性模型；一次性静脉注射高分子右旋糖酐。皮下注射(sc)肾上腺素造成急性高粘滞血症模型，分别用复方丹参滴丸进行治疗，观察血管肉皮细胞分泌功能的变化。结果：慢性高粘滞血症模型血浆血栓素B2(TXB2)和内皮素(ET)浓度非常显升高，而6-酮-前列腺素F1x(6-酮)浓度非常显降低；急性高粘滞血症模型血管内皮分泌功能无显变化；长期使用复方丹参滴丸能调整、改善血管内皮分泌功能的异常状态；复方丹参滴丸改善血管内皮分泌功能的即时效应不显。     

Feasibility of administering mifepristone as a once a month contraceptive pill

Many women find the idea of a once-a-month contraceptive pill an attractive concept. Mifepristone has been shown to be effective as a contraceptive if administered in the early luteal phase. We tested the contraceptive efficacy of 200 mg of mifepristone on day luteinizing hormone (LH) + 2 in a group of 32 women who used a fertility monitor to identify the LH surge. We also recruited a control group, comprising 20 women who were trying to conceive. In this group, 12 women conceived during a total of 50 control cycles (probability of pregnancy 0.25-0.32). Women in the treatment group contributed to a total of 178 cycles and there were two pregnancies (probability of pregnancy 0.01). An LH surge was not detected in 34 cycles (19.1%). In 20 cycles (11.2%) this was due to imperfect use while 14 were monitor method failures (7.9%). Treatment with mifepristone in the early luteal phase did not disrupt the cycle length but women reported slight vaginal bleeding in 15% of the cycles. The combination of a home-use fertility monitor with once-a-month administration of mifepristone (especially if mifepristone is administered at the early luteal phase) is an acceptable contraceptive option with minimal side effects. Unfortunately, it is difficult to envisage how an easier way of defining the correct timing, which required less compliance, could be devised.     

华佗再造丸抗血栓作用及对实验性微循环障碍的影响

目的 观察华佗再造丸对血瘀证动物模型体内血栓,体外血栓的作用及对实验性微循环障碍的影响。方法 实验体国栓采用Ｃｈａｎｄｅｌ法,体内血栓采用动物颈动脉电流刺激法,高分子右旋糖酐造成动物循环障碍。结果 华佗再造丸具有抑制体外全形成、延长体内血栓作用并能降低动物的血液粘度、抑制血小板聚集性,改善动物脑供血供和软脑膜微循环障碍的功能。结论 华佗再造丸具有活血化瘀、拮抗血栓形成的功效,是治疗脑血栓后遗症的     

The public health implications of the 1995 'pill scare'

The warning issued by the UK Committee on Safety Medicines in October 1995, followed by their 'Dear Doctor' letter of October 18, 1995, that oral contraceptive pills containing gestodene or desogestrel were associated with a higher risk of venous thromboembolism has had a negative impact on public heath. A significant number of women either switched brands or ceased contraception altogether following the announcement. National data suggest a strong association between the pill scare and a substantial increase in the number of unintended pregnancies, particularly significant among younger women, with use of oral contraception falling from 40 to 27% of under 16s between 1995-1996 and 1996-1997. The resulting cost of the increase in births and abortions to the National Health Service has been estimated at about Pound Sterling 21 million for maternity care and from Pound Sterling 46 million for abortion provision. The level of risk should, in future, be more carefully assessed and advice more carefully presented in the interests of public health.     

Safety of modern oral contraception: the options for women: lessons to be learned

The relatively short history of hormonal contraception has been marked by a series of 'pill scares', all of which--after creating panic among users--were proven to be unfounded in terms of public health impact. The latest pill scare, provoked by regulatory action in the United Kingdom and the Federal Republic of Germany in response to the publication of a series of articles indicating a doubling of risk of deep venous thrombosis in users of oral contraceptives containing third-generation progestins, seems finally settled: both the British and the German Drug Regulatory Authorities have now reverted their verdict. The damage unfortunately stays: hundreds of thousands of women have been compelled to abandon the pill of their choice, often deciding to drop contraception altogether, thereby exposing themselves to unwanted pregnancy and--in a number of cases--to pregnancy termination. This latest episode should be turned into something positive: we need to learn that, in the case of drugs in widespread use, before restrictive action is taken--and except for very rare and specific instances--the scientific community must carry out an exhaustive debate on the reality and importance of the observed effects. Although the public should, in each instance, be properly informed, it is only after this process has been completed that restrictive action should be taken. It is hoped that, after this last episode, all concerned have learned this simple principle and will accept being guided by it from now on.     

复方软伤伸筋丸治疗膝关节骨性关节炎临床研究

目的 :探讨复方软伤伸筋丸治疗膝关节骨性关节炎的疗效机理。方法 :采用单盲法将膝关节骨性关节炎患者 2 2 0例 ,随机分为软伤伸筋丸组 (治疗组 ) 1 60例 ,壮骨关节丸组 (对照组 ) 60例 ,对比分析两组临床疗效。结果 :1治疗组临床治愈率为 88.75 % ,总有效率为 99.3 5 % ;对照组临床治愈率为 2 3 .3 3 % ,总有效率为 91 .68% ,治疗组优于对照组 ,具有显著性差异 (P<0 .0 1 )。2复方软伤伸筋丸无毒副作用。3复方软伤伸筋丸的应用可使增生骨刺吸收 ,损伤半月板修复。结论 :复方软伤伸筋丸是一种治疗膝关节骨性关节炎安全有效药物。